Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Science 367 , 200204 (2020)
Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial
Diabetes Self-Management Education Patients with T2DM should receive proper education on all aspects of their diabetes management
The medication binds to both receptor types with high affinity, creating a combined effect that exceeds single-receptor targeting approaches
Notably, GIP exerts several metabolic actions on extra-pancreatic tissues including adipose tissue, brain and bone (Fig